Time to challenge 1L mCRPC – a combination treatment to expand options for patients

Training Course • AstraZeneca

About the CPD course

The meeting aims to highlight the key clinical trial data of LYNPARZA (olaparib) combination therapy and discusses the management of AEs and monitoring of patients receiving the combination therapy.

CPD Provider

AstraZeneca

View Profile

Send an enquiry

Full Name*

Email Address*

Contact Number*

Industry*

Your Enquiry*

By submitting this form, you consent to CPD sending you email regarding your application.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca

At AstraZeneca, we are transforming the future of healthcare by unlocking the power of what science can do – for people, society and the planet. The UK plays a key role within the global AstraZeneca network. It is home to colleagues from across the full life sciences value chain. Everything we do is driven by science to transform healthcare and patient outcomes, while playing a purpose-led role in wider society.